BofA Securities Double Downgrades Lyra Therapeutics (LYRA) to Underperform
Tweet Send to a Friend
BofA Securities analyst Jason Gerberry downgraded Lyra Therapeutics (NASDAQ: LYRA) from Buy to Underperform with a price target of $0.35.The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
